Bridging the translation bottleneck: China’s “Catfish Moment” for biomedical advanced technologies
Abstract
Research and Clinical Translational Application of New Biomedical Technologies (State Council Decree No. 818, hereafter Order 818) took effect.1 Widely viewed as China's "Catfish Moment," this landmark regulation is expected to revitalize a stagnant clinical translation system.By clarifying regulatory pathways, it could unlock accumulated results from investigator-initiated trials (IITs) and foster greater collaboration among industry, hospitals, and research institutions in advancing biomedical technologies such as cell and gene therapy. INNOVATION LANDSCAPE AND TRANSFORMATION PROSPECTSOver the past decade, clinical trials of innovative pharmaceutical products in China have experienced explosive growth.Its share of interventional trials
Publication details
- Journal / source
- The Innovation Medicine
- Publisher
- Innovation Press Co., Limited
- Volume
- 4
- Issue
- 3
- Pages
- 100236–100236
- Publication date
- 1 January 2026